SG11201806599SA - Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human - Google Patents
Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in humanInfo
- Publication number
- SG11201806599SA SG11201806599SA SG11201806599SA SG11201806599SA SG11201806599SA SG 11201806599S A SG11201806599S A SG 11201806599SA SG 11201806599S A SG11201806599S A SG 11201806599SA SG 11201806599S A SG11201806599S A SG 11201806599SA SG 11201806599S A SG11201806599S A SG 11201806599SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- stopping
- human
- preventing
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title abstract 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 title abstract 3
- 239000003149 muscarinic antagonist Substances 0.000 title abstract 3
- 239000000043 antiallergic agent Substances 0.000 title abstract 2
- 230000004329 axial myopia Effects 0.000 title abstract 2
- 229940052760 dopamine agonists Drugs 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 201000004624 Dermatitis Diseases 0.000 abstract 1
- 230000003266 anti-allergic effect Effects 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 230000001022 anti-muscarinic effect Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 230000003291 dopaminomimetic effect Effects 0.000 abstract 1
- 239000003889 eye drop Substances 0.000 abstract 1
- 229940012356 eye drops Drugs 0.000 abstract 1
- 230000006870 function Effects 0.000 abstract 1
- 230000000642 iatrogenic effect Effects 0.000 abstract 1
- 230000004379 myopia Effects 0.000 abstract 1
- 208000001491 myopia Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/140846 Al 24 August 2017 (24.08.2017) WIPO I PCT 111111111111110111011111111111010111110 01011111111111110111111111111111111110111111 (51) International Patent Classification: A61K 9/00 (2006.01) A61K 31/46 (2006.01) A61K 9/08 (2006.01) A61K 36/535 (2006.01) A61K 31/4535 (2006.01) (21) International Application Number: PCT/EP2017/053619 (22) International Filing Date: 17 February 2017 (17.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 102016000017487 19 February 2016 (19.02.2016) IT (72) Inventor; and (71) Applicant : D'AMBROSIO, Enzo Maria [IT/IT]; Cortile dei Fiori, 6, 74024 Manduria (IT). AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (74) Agents: VALENZA, Silvia et al.; NOTARBARTOLO & Published: GERVASI S.P.A., Corso di Porta Vittoria 9, 20122 Milano (IT). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, with international search report (Art. 21(3)) W O 20 17 / 1408 46 Al (54) Title: COMBINATION OF AN ANTIALLERGIC AGENT WITH MUSCARINIC ANTAGONIST AND/OR DOPAMINER- GIC AGONIST FOR USE IN PREVENTING/STOPPING OF AXIAL MYOPIA IN HUMAN (57) : One of the major issues against the use of muscarinic antagonists or dopamine agonist eyedrops for the controlling of eye growth and prevention of myopia is the unacceptable rate of iatrogenic conjunctivitis or dermatitis. This invention relates to the association of those active principles with an antiallergic component. In alternative the ophthalmic use of a molecule that simultan- eously has an antimuscarinic and/or dopaminergic action along with an antihistaminic function.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITUB2016A000876A ITUB20160876A1 (en) | 2016-02-19 | 2016-02-19 | COMBINATION OF AN ANTIALLERGIC AGENT WITH A MUSCARIN ANTAGONIST AND / OR A DOPAMINERGIC AGONIST FOR THE USE IN PREVENTION / ARREST OF MIOPIA IN THE MAN |
| PCT/EP2017/053619 WO2017140846A1 (en) | 2016-02-19 | 2017-02-17 | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806599SA true SG11201806599SA (en) | 2018-09-27 |
Family
ID=55948995
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806599SA SG11201806599SA (en) | 2016-02-19 | 2017-02-17 | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human |
| SG10202007417SA SG10202007417SA (en) | 2016-02-19 | 2017-02-17 | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202007417SA SG10202007417SA (en) | 2016-02-19 | 2017-02-17 | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20200253951A1 (en) |
| EP (1) | EP3416617A1 (en) |
| JP (1) | JP2019505542A (en) |
| KR (1) | KR20180117642A (en) |
| CN (1) | CN108883060A (en) |
| AU (1) | AU2017220640B2 (en) |
| BR (1) | BR112018016845A2 (en) |
| CA (1) | CA3013846A1 (en) |
| CL (1) | CL2018002196A1 (en) |
| IL (1) | IL260893B2 (en) |
| IT (1) | ITUB20160876A1 (en) |
| SG (2) | SG11201806599SA (en) |
| WO (1) | WO2017140846A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT201800005599A1 (en) * | 2018-05-22 | 2019-11-22 | Soft contact lens | |
| CN109044965A (en) * | 2018-10-17 | 2018-12-21 | 广州大光制药有限公司 | The medical composite for eye and medical usage of glycopyrronium bromide |
| CA3181292A1 (en) * | 2020-06-02 | 2021-12-09 | Andrei V. Tkatchenko | Methods and compositions for preventing and treating myopia with levocabastine, a selective histamine h1-receptor antagonist, and derivatives thereof |
| CN114558069A (en) * | 2022-04-06 | 2022-05-31 | 杭州美依生物科技有限公司 | Eye-soothing smearing liquid and preparation method thereof |
| CN115137314B (en) * | 2022-09-02 | 2022-11-15 | 首都医科大学附属北京同仁医院 | Myopia risk assessment method and device and wearable device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69029734T2 (en) | 1989-06-21 | 1997-05-28 | Univ Pennsylvania | Use of pirenzepine, telenzepine or O-methoxy -sila-hexocyclium for the manufacture of a medicament for the TREATMENT AND REGULATION OF EYE DEVELOPMENT |
| CA2567981C (en) | 2004-05-28 | 2010-08-31 | Schering Corporation | Constrained himbacine analogs as thrombin receptor antagonists |
| EP1853592B1 (en) | 2005-01-14 | 2011-03-02 | Schering Corporation | Synthesis of himbacine analogs |
| US20080050335A1 (en) * | 2006-07-25 | 2008-02-28 | Osmotica Corp. | Ophthalmic Solutions |
| SG151148A1 (en) * | 2007-10-05 | 2009-04-30 | Singapore Health Services Pte | Method and/or kit for determining response to muscarinic receptor antagonist treatment |
| ITMO20100369A1 (en) * | 2010-12-30 | 2012-07-01 | Enable Innovations Srl | RANGE OF PRODUCTS FOR OPHTHALMIC USE. |
-
2016
- 2016-02-19 IT ITUB2016A000876A patent/ITUB20160876A1/en unknown
-
2017
- 2017-02-17 EP EP17710482.5A patent/EP3416617A1/en active Pending
- 2017-02-17 BR BR112018016845A patent/BR112018016845A2/en not_active Application Discontinuation
- 2017-02-17 JP JP2018543132A patent/JP2019505542A/en active Pending
- 2017-02-17 AU AU2017220640A patent/AU2017220640B2/en active Active
- 2017-02-17 CN CN201780011993.4A patent/CN108883060A/en active Pending
- 2017-02-17 US US15/999,784 patent/US20200253951A1/en not_active Abandoned
- 2017-02-17 SG SG11201806599SA patent/SG11201806599SA/en unknown
- 2017-02-17 WO PCT/EP2017/053619 patent/WO2017140846A1/en active Application Filing
- 2017-02-17 KR KR1020187026872A patent/KR20180117642A/en not_active Application Discontinuation
- 2017-02-17 SG SG10202007417SA patent/SG10202007417SA/en unknown
- 2017-02-17 CA CA3013846A patent/CA3013846A1/en active Pending
-
2018
- 2018-07-31 IL IL260893A patent/IL260893B2/en unknown
- 2018-08-09 CL CL2018002196A patent/CL2018002196A1/en unknown
-
2023
- 2023-01-12 US US18/096,165 patent/US20230172904A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CL2018002196A1 (en) | 2019-01-25 |
| IL260893A (en) | 2018-09-20 |
| SG10202007417SA (en) | 2020-09-29 |
| IL260893B1 (en) | 2023-04-01 |
| BR112018016845A2 (en) | 2018-12-26 |
| US20230172904A1 (en) | 2023-06-08 |
| KR20180117642A (en) | 2018-10-29 |
| AU2017220640B2 (en) | 2022-08-25 |
| JP2019505542A (en) | 2019-02-28 |
| CN108883060A (en) | 2018-11-23 |
| WO2017140846A1 (en) | 2017-08-24 |
| EP3416617A1 (en) | 2018-12-26 |
| RU2018133026A (en) | 2020-03-19 |
| AU2017220640A1 (en) | 2018-10-04 |
| US20200253951A1 (en) | 2020-08-13 |
| IL260893B2 (en) | 2023-08-01 |
| ITUB20160876A1 (en) | 2017-08-19 |
| RU2018133026A3 (en) | 2020-04-24 |
| CA3013846A1 (en) | 2017-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806599SA (en) | Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201907435PA (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| SG11201900596XA (en) | Cannabis composition | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900665VA (en) | Cannabis composition | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201809822SA (en) | Atropine-containing aqueous composition | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201902974PA (en) | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201808650QA (en) | Methods of treating ocular conditions | |
| SG11201811093RA (en) | Antimicrobial compounds and methods for use thereof | |
| SG11201811655SA (en) | Trpa1 antagonists for treatment of dry eye, ocular pain and inflammation | |
| SG11201900336YA (en) | Radioligands for imaging the ido1 enzyme |